Releases
See all
Releases
19. June, 2025
Strengthening Executive Management with the promotion of Martin Juhl
On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of...
Releases
28. May, 2025
Positive top-line results from its final CT001 Study 0202
On 28 May – Cessatech A/S (“Cessatech” or “the Company”) announces top-line results from...
Releases
28. February, 2025
Annual Report 2024
Today, Friday 28. February, Cessatech has released the Annual Report for 20024. We have...
Releases
4. February, 2025
Positive Notified Body opinion under MDR for CT001
On 4 February – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...
Releases
16. October, 2024
Halfway milestone patient recruitment in Paediatric Study 0202
Cessatech announces that recruitment has today reached the halfway point for patient recruitment with...
Facts about Children
See all
Facts
18. March, 2024
Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions
More than 20 million children annually, alone in Europe, are subject to acute pain...
Facts
12. February, 2024
Treating children is not just like treating small adults
Giving medicine to children can’t be a one-size-fits-all approach. Their changing anatomy and...
Facts
25. August, 2023
New findings supporting CT001
Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...
Facts
15. March, 2022
Off-label use of medication in children continue to be the rule rather than the exception…
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See detailsStay up to date!
Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.